X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psychedelic drug
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Core One Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2021
Details:
The acquisition of Akome further positions the Company at the forefront of development of psychedelic drugs for neurological diseases and mental disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: BB106
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
The USPTO has granted Bexson U.S Patent, describing pharmaceutical formulations and treatment methods including BB106. BB106 is formulated for subcutaneous delivery, which could make ketamine-based pain management a viable alternative to opioids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Neurology Product Name: Undisclosed
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
